US Chamber of Commerce wants court to eliminate IRS rule that blocked Pfizer's acquisition of Allergan; AbbVie hit with second suit over its 2014 proposed acquisition of Shire.

Celgene Corp. has deepened its investment in antibody R&D, striking a collaboration with Sutro Biopharma to design and develop next-gen antibodies and to manufacture a proprietary Celgene candidate. Sutro gets cash, biobucks, and hi-profile validation of its multi-faceted non-cell antibody platform.

Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.